---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-003816"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:37:05.457930+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology reports Q4/FY2021 results; mCRC trial shows 34% ORR; Pfizer invests $15M

## Summary
- Onvansertib+FOLFIRI/bevacizumab in KRAS-mutated mCRC: 34% (12/35) ORR at RP2D; mPFS 9.4 months vs ~4.5-5.7 months historical control.
- Cash, equivalents, and short-term investments $141M as of Dec 31, 2021; Q4 operating expenses $9.6M (up from $6.6M in 2020).
- Pfizer invested $15M via equity purchase of 2.4M shares at $6.22 (19% premium); Pfizer executive to join Scientific Advisory Board.
- Appointed Tod Smeal as CSO (ex-Eli Lilly, Pfizer) and Charles Monahan as SVP Regulatory Affairs.
- Full year 2021 net cash used in operating activities $23.0M vs $16.3M in 2020.

## SEC filing metadata
- accession: 0001628280-22-003816
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022003816/0001628280-22-003816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022003816/crdf-20220224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-003816
- JSON: https://secwatch.observer/filing/0001628280-22-003816.json
- Plain text: https://secwatch.observer/filing/0001628280-22-003816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.